Effectiveness of antiretroviral therapy in treatment-naïve patients. Results at 24 and 48 weeks
More details
Hide details
Hospital Universitario Son Espases, Palma de Mallorca, Spain
Hospital Son Llàtzer, Palma de Mallorca, Spain
Submission date: 2018-06-25
Acceptance date: 2019-05-20
Publication date: 2019-07-11
HIV & AIDS Review 2019;18(2):100-106
Since 2015, integrase strand transfer inhibitors (INSTI)-based regimens have been considered as the preferred option for antiretroviral therapy (ART)-naive patients. The main objective of this study was to identify the ART-regimens selected for treatment-naïve patients during 2015 in two tertiary hospitals, determine the rate of virological failure at 24 and 48 weeks, and compare the results with those of previous years (2012-2014).

Material and methods:
Four-year retrospective study. Adult ART-naïve patients who had started treatment between 2012 and 2015 were selected. Clinical data, laboratory tests performed, and ART selected were recorded.

A total of 536 patients were included, 137 from 2015 and 399 from 2012-2014. The most common ART regimens prescribed in 2015, compared to 2012-2014, were INSTI-based regimens (68.6% vs. 4.8%), followed by non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens (20.4% vs. 52.8%) and PI-based regimens (10.9% vs. 42.5%). Most patients received a single-tablet regimen (78.8% vs. 51.9%). In 2015, 72.3% of patients had a viral load (VL) < 50 copies/ml at week 24 and 83.9% at week 48, compared to 55.1% and 74.7%, respectively, in 2012-2014. During the 48-week follow-up, the ART regimen was changed in 22.6% of patients in 2015 and 29.3% in 2012-2014. The main reason was simplification (45.2% vs. 22.2%) followed by side effects (25.8% vs. 38.5%).

In 2015, INSTI-based regimens were prescribed in nearly 70% of ART-naïve patients. This change in trend in the starting ART regimen results in a greater number of patients achieving a VL < 50 copies/ml at weeks 24 and 48 and in a reduction in ART changes due to adverse effects.

Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos con infección por el virus de la inmunodeficiencia humana, 2016. Available at: guiasclinicas/2016/gesida-guiasclinicas-2016-tar.pdf (Accessed: 06.12.2016).
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2016. Available at: adultandadolescentgl.pdf (Accessed: 06.12.2016).
European Guidelines for treatment of HIV-infected adults in Europe, 2015. Available at: (Accessed: 06.12.2016).
INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015; 373: 795-807.
TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 2015; 373: 808-822.
Cescon AM, Cooper C, Chan K, et al. Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort. HIV Med 2011; 12: 352-360.
Street E, Curtis H, Sabin CA, et al., British HIV Association (BHIVA) and BHIVA Audit and Standards Subcommittee. British HIV Association (BHIVA) national cohort outcomes audit of patients commencing antiretrovirals from naive. HIV Med 2009; 10: 337-342.
Suarez-Garcia I, Sobrino-Vegas P, Tejada A, et al. Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort. HIV Med 2014; 15: 86-97.
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach - Second edition. World Health Organization, 2016. Available at: file:///C:/Users/BEEP/ Downloads/9789241549684_eng.pdf (Accessed: 06.12.2016).
Grupo de expertos del Plan Nacional sobre el sida y de la Sociedad Espańola de Geriatría y Gerontología. Documento de Consenso sobre edad avanzada e Infección por el virus de la inmunodeficiencia humana, 2015. Available at: (Accessed: 06.20.2016).
Área de Vigilancia de VIH y Comportamientos de Riesgo. Vigilancia Epidemiológica del VIH y sida en Espańa: Sistema de Información sobre Nuevos Diagnósticos de VIH y Registro Nacional de Casos de Sida. Plan Nacional sobre el Sida - S.G. de Promoción de la Salud y Epidemiología / Centro Nacional de Epidemiología - ISCIII. Madrid, November 2016. Available at: (Accessed: 08.17.2017).
12 Keita M, Perbost I, Pugliese-Wehrlen S, et al. Incidences and risk factors of first-line HAART discontinuation: a limitation to the success of the “seek, test, treat, and retain” strategy? AIDS Care 2014; 26: 1058-1069.
Jarrin I, Hernandez-Novoa B, Alejos B, et al. Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010. Antivir Ther 2013; 18: 161-170.
Antiretroviral Therapy Cohort Collaboration (ART-CC), Vandenhende MA, Ingle S, May M, et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS 2015; 29: 373-383.
Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis 2013; 57: 1489-1496.
Boillat-Blanco N, Darling KE, Schoni-Affolter F, et al. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study. Antivir Ther 2015; 20: 165-175.
Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2017), 2017. Available at: 02/gesida-guiasclinicas-2017-TAR.pdf (Accessed: 08.20. 2017).
Pedrol E, Viciana P, Arranz A, et al. Reasons for antiretroviral treatment change in HIV+ patients in Spain in 2010-2011. SWITCH AUDIT Study. Rev Esp Quimioter 2014; 27: 93-97.
de la Torre J, Santos J, Perea-Milla E, Perez I, et al. First antiretroviral therapy regimen in HIV-infected patients. Durability and factors associated with therapy changes. Enferm Infecc Microbiol Clin 2008; 26: 416-422.
Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open 2013; 3. doi: 10.1136/bmjopen-2013-003028.
Journals System - logo
Scroll to top